Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 23.09 Million SEK | 10.48% |
| 2022 | 20.9 Million SEK | 5.05% |
| 2021 | 19.89 Million SEK | 36.11% |
| 2020 | 14.61 Million SEK | 14.85% |
| 2019 | 12.72 Million SEK | -5.59% |
| 2018 | 13.48 Million SEK | 13.48% |
| 2017 | 11.88 Million SEK | 113.39% |
| 2016 | 5.56 Million SEK | 185575366.67% |
| 2015 | 3.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.72 Million SEK | 12.15% |
| 2024 Q2 | 6.72 Million SEK | 0.0% |
| 2023 Q2 | 11.78 Million SEK | 109.59% |
| 2023 Q4 | 5.99 Million SEK | 0.0% |
| 2023 FY | 23.09 Million SEK | 10.48% |
| 2023 Q3 | 5.99 Million SEK | -49.1% |
| 2023 Q1 | 5.62 Million SEK | -45.95% |
| 2022 Q2 | 4.93 Million SEK | 0.0% |
| 2022 Q4 | 10.4 Million SEK | 89.98% |
| 2022 Q3 | 5.47 Million SEK | 10.85% |
| 2022 Q1 | 4.93 Million SEK | -47.56% |
| 2022 FY | 20.9 Million SEK | 5.05% |
| 2021 Q1 | 4.59 Million SEK | 19.75% |
| 2021 Q2 | 4.59 Million SEK | 0.0% |
| 2021 Q3 | 4.65 Million SEK | 1.46% |
| 2021 Q4 | 9.41 Million SEK | 102.12% |
| 2021 FY | 19.89 Million SEK | 36.11% |
| 2020 Q4 | 3.83 Million SEK | 0.0% |
| 2020 Q2 | 2.78 Million SEK | 0.0% |
| 2020 Q3 | 3.83 Million SEK | 37.92% |
| 2020 FY | 14.61 Million SEK | 14.85% |
| 2020 Q1 | 2.78 Million SEK | -11.67% |
| 2019 Q3 | 3.14 Million SEK | 27.01% |
| 2019 FY | 12.72 Million SEK | -5.59% |
| 2019 Q4 | 3.14 Million SEK | 0.0% |
| 2019 Q2 | 2.47 Million SEK | 0.0% |
| 2019 Q1 | 2.47 Million SEK | 0.0% |
| 2018 FY | 13.48 Million SEK | 13.48% |
| 2017 FY | 11.88 Million SEK | 113.39% |
| 2016 FY | 5.56 Million SEK | 185575366.67% |
| 2015 FY | 3.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 72.13% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 96.226% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 96.226% |
| Arcoma AB | 53.25 Million SEK | 56.639% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -364.691% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.189% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 89.028% |
| CellaVision AB (publ) | 295.99 Million SEK | 92.199% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 66.501% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -1663.735% |
| C-Rad AB (publ) | 3.8 Million SEK | -507.645% |
| Duearity AB (publ) | 21.58 Million SEK | -6.975% |
| Dignitana AB (publ) | 74.73 Million SEK | 69.104% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -755.204% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.785% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -26.672% |
| Iconovo AB (publ) | 63.35 Million SEK | 63.553% |
| Integrum AB (publ) | 90.57 Million SEK | 74.506% |
| Mentice AB (publ) | 237.06 Million SEK | 90.26% |
| OssDsign AB (publ) | 175.6 Million SEK | 86.851% |
| Paxman AB (publ) | 133.8 Million SEK | 82.743% |
| Promimic AB (publ) | 48.55 Million SEK | 52.442% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 85.78% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 67.002% |
| ScandiDos AB (publ) | 61.03 Million SEK | 62.17% |
| Sectra AB (publ) | 39.06 Million SEK | 40.889% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 86.77% |
| Senzime AB (publ) | 141.51 Million SEK | 83.684% |
| SpectraCure AB (publ) | 12.12 Million SEK | -90.39% |
| Stille AB | 87.21 Million SEK | 73.526% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.585% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 94.763% |